Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

TAcTIC

Financiado

TArgeTed molecular Imaging and surgery for gastro intestinal Cancer

The treatment for cancer patients is shifting from population-based treatment to the more precise personalized medicine. Tumor-specific molecular diagnostics and treatment are an example of this phenomena to assist clinical decisi... ver más

31/01/2021

Leiden University...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

ACADEMISCH ZIEKENHUIS LEIDEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-01-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2018-PoC: ERC Proof of Concept Grant

I+D

Cerrada hace 6 años

0% 100% 100%

3 Participantes

Leiden University Medical Ce...

128.75K€ | Lider

IZURZA PRODUCTOS CALORIFUGOS

CHDR

21.25K€ | Participante

Proyectos interesantes

FG_WIT AUTOMATED PROTOTYPE OF CANCER DETECTION FROM CTDNA 75K€ Cerrado

CTQ2017-85658-R TG-DIAG: NUEVAS ESTRATEGIAS DE DIAGNOSTICO BASADAS EN FLUORE... 116K€ Cerrado

CANCER-ID Cancer treatment and monitoring through identification of ci... 21M€ Cerrado

MONOBREAST Low-dose breast CT with monochromatic x-ray sources 150K€ Cerrado

GUIDE.MRD GUIding multi-moDal thErapies against MRD by liquid biopsies... 34M€ Cerrado

PDC2021-121424-I00 BIOPSIA Y TEJIDO EN UN CHIP MAS BIOSENSORES MULTIPLEXADOS IN... 138K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 18 meses Fecha Inicio: 2019-07-11
Fecha Fin: 2021-01-31

Líder del proyecto

ACADEMISCH ZIEKENHUIS LEIDEN

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto The treatment for cancer patients is shifting from population-based treatment to the more precise personalized medicine. Tumor-specific molecular diagnostics and treatment are an example of this phenomena to assist clinical decision making and to improve treatment strategies for patients. This change in management will lead to societal benefits such as treatments that fits the patient’s needs and therefore, increased health benefits and increased quality-of-life. The targeted agent we have developed has both an imaging version to improve the detection and resection of cancer and an cytotoxic variant to eliminate potential remaining tumor cells. At this point, there is no agent available that can contribute to both the diagnostic phase and the subsequent treatment in a tumor-specific manner. Near infrared (NIR) fluorescence imaging is a technique that has gained a lot of attention over the last decade because of its role in intra-operative guidance to improve resection, and in, for example, endoscopy to improve detection. Combining a NIR-dye to a specific tumor-targeting ligand, like an antibody or a peptide, dramatically enhances the specificity, providing a solid real-time identification and demarcation technique. In TAcTIC, we propose the clinical introduction of a targeted fluorescent imaging agent against EpCAM, which can also be used for response monitoring during endoscopy, and the initiation of a New Company (in the Netherlands) via a joint venture between LUMC and ElevenBio (Boston, United States) for the future commercialization of this agent. The expected outcomes of this proof-of-concept project are the successful introduction of a novel targeted fluorescent agent for in multiple cancer types, a joint venture between LUMC and ElevenBio for the commercialization of this agent, and societal benefits for the patient in the form of increased health benefits and quality of life due to a treatment strategy that fits the individual patient’s needs.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores